Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATHE NASDAQ:DTIL NASDAQ:KLTO NASDAQ:NERV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHEAlterity Therapeutics$5.01-1.0%$4.57$1.00▼$7.00$44.87M0.66205,931 shs45,942 shsDTILPrecision BioSciences$4.62-2.7%$4.75$3.61▼$11.09$52.67M1.52216,125 shs61,917 shsKLTOKlotho Neurosciences$0.92-4.6%$1.09$0.11▼$3.91$44.39M10.925.91 million shs854,429 shsNERVMinerva Neurosciences$1.93+2.9%$1.80$1.15▼$3.00$13.37M-0.3220,799 shs2,623 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHEAlterity Therapeutics-0.99%-23.51%+24.01%+46.28%+213.14%DTILPrecision BioSciences-2.74%-10.29%+8.45%-19.65%-51.52%KLTOKlotho Neurosciences-4.55%-25.21%-22.70%+426.26%+91,989,900.00%NERVMinerva Neurosciences+0.79%-9.62%+12.90%+13.24%-35.19%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATHEAlterity Therapeutics1.7605 of 5 stars3.33.00.00.01.11.70.0DTILPrecision BioSciences4.0855 of 5 stars3.53.00.04.60.61.71.3KLTOKlotho NeurosciencesN/AN/AN/AN/AN/AN/AN/AN/ANERVMinerva Neurosciences2.7494 of 5 stars3.03.00.04.60.00.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATHEAlterity Therapeutics 2.50Moderate Buy$12.00139.52% UpsideDTILPrecision BioSciences 3.00Buy$47.00917.32% UpsideKLTOKlotho Neurosciences 0.00N/AN/AN/ANERVMinerva Neurosciences 2.00Hold$5.00159.74% UpsideCurrent Analyst Ratings BreakdownLatest NERV, ATHE, DTIL, and KLTO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025DTILPrecision BioSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATHEAlterity TherapeuticsN/AN/AN/AN/A$1.04 per shareN/ADTILPrecision BioSciences$68.70M0.75N/AN/A$6.87 per share0.67KLTOKlotho NeurosciencesN/AN/AN/AN/A$0.04 per shareN/ANERVMinerva NeurosciencesN/AN/A$0.22 per share8.95($3.67) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATHEAlterity Therapeutics-$12.54MN/A0.00∞N/AN/AN/AN/A8/4/2025 (Estimated)DTILPrecision BioSciences$7.17M-$2.01N/AN/AN/A-42.99%-69.26%-29.30%8/7/2025 (Estimated)KLTOKlotho Neurosciences-$6.15M-$0.36N/A∞N/AN/A-1,779.01%-275.01%8/18/2025 (Estimated)NERVMinerva Neurosciences$1.44M$0.822.35N/AN/AN/A-20.68%15.73%8/5/2025 (Estimated)Latest NERV, ATHE, DTIL, and KLTO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025DTILPrecision BioSciences-$0.09N/AN/AN/A$6.27 millionN/A8/5/2025Q2 2025NERVMinerva Neurosciences-$0.95N/AN/AN/AN/AN/A5/15/2025Q1 2025DTILPrecision BioSciences-$0.43-$2.21-$1.78-$2.21$5.00 million$0.03 million5/15/2025Q1 2025KLTOKlotho NeurosciencesN/A-$0.08N/A-$0.08N/AN/A5/13/2025Q1 2025NERVMinerva Neurosciences-$1.07-$0.50+$0.57-$0.50N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATHEAlterity TherapeuticsN/AN/AN/AN/AN/ADTILPrecision BioSciencesN/AN/AN/AN/AN/AKLTOKlotho NeurosciencesN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATHEAlterity TherapeuticsN/A3.84N/ADTILPrecision BioSciences0.456.626.62KLTOKlotho NeurosciencesN/A0.290.29NERVMinerva NeurosciencesN/A9.219.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATHEAlterity Therapeutics2.14%DTILPrecision BioSciences37.99%KLTOKlotho Neurosciences20.07%NERVMinerva Neurosciences34.56%Insider OwnershipCompanyInsider OwnershipATHEAlterity Therapeutics38.80%DTILPrecision BioSciences4.50%KLTOKlotho Neurosciences26.70%NERVMinerva Neurosciences8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATHEAlterity Therapeutics108.87 million5.43 millionNot OptionableDTILPrecision BioSciences20011.09 million10.59 millionNo DataKLTOKlotho NeurosciencesN/A46.05 million33.76 millionN/ANERVMinerva Neurosciences96.99 millionN/ANot OptionableNERV, ATHE, DTIL, and KLTO HeadlinesRecent News About These CompaniesChandigarh: Minerva enter knockout stage of Gothia Cup 2025July 17, 2025 | msn.comMinerva CEO navigates 'nightmare' lab market to secure new HQ in WoburnJuly 16, 2025 | bizjournals.comMinerva University Named World's Most Innovative University for Fourth Consecutive YearJuly 15, 2025 | uk.finance.yahoo.comFree concert on Minerva’s Municipal Park StageJuly 14, 2025 | morningjournalnews.comMHelsinki Cup: Minerva Academy in Round-16 with thumping 7-0 winJuly 14, 2025 | msn.comMinerva narrowly fell short in final, but won hearts with historic Helsinki Cup campaignJuly 13, 2025 | english.newsnationtv.comEMinerva Academy FC: Defying Odds and Dazzling Europe in Helsinki Cup-2025July 13, 2025 | devdiscourse.comDHelsinki Cup: Minerva Academy in semi-finals, two Finland clubs eliminatedJuly 12, 2025 | english.newsnationtv.comEMinerva Neurosciences Inc. (NERV) Stock Price Today - WSJJuly 11, 2025 | wsj.comMinerva registers fourth win in Helsinki CupJuly 10, 2025 | msn.comHelsinki Cup: Minerva Academy logs twin victoriesJuly 10, 2025 | msn.comMinerva Academy FC's Triumph: An Unstoppable Force in Helsinki Cup 2025July 10, 2025 | devdiscourse.comDHelsinki Cup: Minerva registered its fourth win, creating history by winning the match 9-0July 10, 2025 | news.webindia123.comNMinerva High School Athletic Hall of Fame announces Class of 2025 membersJuly 10, 2025 | msn.comValCUN installs Minerva metal Additive Manufacturing machine at Johns Hopkins UniversityJuly 8, 2025 | metal-am.comMMinerva Avenue Charting Next Steps Following Sudden FireJuly 8, 2025 | msn.comFire destroys popular North Nashville nightclub Minerva AvenueJuly 6, 2025 | msn.comMinerva nights event to include music, food, gamesJune 27, 2025 | cantonrep.comCNordic Capital invests in CRO and CDMO Minerva ImagingJune 11, 2025 | pehub.comMinerva Neurosciences, Inc: Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business UpdatesMay 14, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonHow a Government Loan Changes the Game for Plug PowerBy Jeffrey Neal Johnson | July 4, 2025View How a Government Loan Changes the Game for Plug PowerAmazon's Pre-Earnings Setup Is Almost Too Clean—Red Flag?By Sam Quirke | July 29, 2025View Amazon's Pre-Earnings Setup Is Almost Too Clean—Red Flag?Will Hims & Hers Fall Along With Novo Nordisk?By Gabriel Osorio-Mazilli | August 1, 2025View Will Hims & Hers Fall Along With Novo Nordisk?NERV, ATHE, DTIL, and KLTO Company DescriptionsAlterity Therapeutics NASDAQ:ATHE$5.01 -0.05 (-0.99%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.99 -0.02 (-0.50%) As of 08/1/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.Precision BioSciences NASDAQ:DTIL$4.62 -0.13 (-2.74%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.62 +0.00 (+0.11%) As of 08/1/2025 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Klotho Neurosciences NASDAQ:KLTO$0.92 -0.04 (-4.55%) As of 08/1/2025 04:00 PM EasternKlotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.Minerva Neurosciences NASDAQ:NERV$1.92 +0.06 (+2.94%) Closing price 08/1/2025 03:45 PM EasternExtended Trading$1.92 0.00 (0.00%) As of 08/1/2025 04:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
